Compare Organon & Co. Common Stock (OGN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs US Bancorp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while US Bancorp trades at $56.5 (market cap $88.64B). The key difference: US Bancorp is far larger — about 24.5× Organon & Co. Common Stock's market cap, and US Bancorp pays the higher dividend (3.8%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and US Bancorp for 98 Days on average.
| OGN | USB | |
|---|---|---|
Market Cap | $3.62B | $88.64B |
Volume | 2,892,999 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $13.81 | $65.42 |
52-Week Low | $5.70 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $11.04B | $118.14B |
Dividend Yield | 0.58% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
U.S. Bancorp (USB) trades at $56.26, down 2.02% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with a P/E of 11.36 and net income margin of 27.61%, having beaten earnings estimates for three consecutive quarters. Recent news highlights dividend increases and strong Q3 expectations, while analyst consensus remains positive with a $69.94 price target.
USB presents a value opportunity with attractive valuation metrics and consistent earnings outperformance, though near-term technical weakness and regulatory uncertainties pose risks. The stock's 3.8% dividend increase signals management confidence, but investors should monitor interest rate sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
